For the quarter ended December 2025, Agilon Health (AGL) reported revenue of $1.57 billion, up 3.1% over the same period last year. EPS came in at -$0.46, compared to -$0.25 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.46 billion, representing a surprise of +7.82%. The company delivered an EPS surprise of -71.64%, with the consensus EPS estimate being -$0.27.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Avg. Medicare Advantage Members: 540,000 versus 503,800 estimated by two analysts on average.
- Revenues- Other operating: $2.51 million versus $3.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -22.7% change.
- Revenues- Medical services: $1.57 billion versus $1.45 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.
View all Key Company Metrics for Agilon here>>>
Shares of Agilon have returned -39.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilon Health, Inc. (AGL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
